Roche says Alzheimer’s antibody gets U.S. breakthrough designation By Reuters
[ad_1]
© Reuters. FILEPHOTO: This sign can be seen at White Oak headquarters of Food and Drug Administration in Maryland on August 29, 2020. REUTERS/Andrew KellyZURICH, Reuters – Roche has announced that the breakthrough therapy designation for Alzheimer’s disease treatment from the U.S. Food and Drug Administration was given to its gantenerumab protein.
In a statement, the Swiss pharmaceutical giant stated that it expects further information on the ongoing Phase III study to be completed in 2022’s second half.
Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.
Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes, charts and sell/buy signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.
[ad_2]